Crescent Biopharma, Inc. · NASDAQ:CBIO
Crescent Biopharma — Investor Presentation (November 2024)
26 slides from Crescent Biopharma's investor presentation, Nov 18, 2024
Slide 1: Crescent Biopharma Overview
Crescent Biopharma Overview November 2024
Slide 2: Disclaimer
Disclaimer This presentation is for informational purposes only and only a summary of certain information related to the Company. It does not purport to be complete and does not contain all information that an investor may need to consider in making an investment decision. The information contained
Slide 3: Crescent aims to advance the next wave of innovation in cancer therapy
Crescent Biopharma aims to advance the next wave of innovation in cancer therapy Crescent’s pipeline consists of potentially best-in-class therapies for the treatment of solid tumors. • Crescent is the fifth company Stage launched with assets discovered Potential Program MoA IND- and in-house by Par
Slide 4: Three highly impactful oncology programs with best-in-class potential
Crescent is advancing three highly impactful oncology programs with best-in-class potential CR-001 CR-002 & CR-003 PD-1 x VEGF cooperative tetravalent bsAb; ADCs with topoisomerase inhibitor payloads; same MoA as ivonescimab potentially best-in-class Anti-VEGF • Designed to reproduce • Two unique, u
Slide 5: Multiple ways to win: pipeline enables optionality with combination therapies
Multiple ways to win: Crescent pipeline enables optionality with differentiating combination therapies Optimized Novel Monotherapies Synergistic Combination Approaches CR-001 CR-002 CR-003 CR-001 + CR-002 CR-001 + CR-003 Engineered for: Selected for: Best-in class efficacy Safety Mechanism of action
Slide 6: PD-(L)1-targeted therapies, annualizing $50B+, have transformed oncology
PD-(L)1-targeted therapies, annualizing $50B+, have transformed oncology – with Keytruda now the best-selling drug in the world PD-(L)1 inhibitors have significantly prolonged survival, PD-(L)1-targeted therapies are one of the largest drug classes, shifting 1L treatment to immunotherapy with Keytru
Slide 7: Ivonescimab doubled progression-free survival vs. Keytruda in a P3 NSCLC trial
Ivonescimab, a cooperative PD-1 x VEGF bispecific, doubled progression-free survival vs. Keytruda in a P3 NSCLC trial Ivonescimab is the first drug to demonstrate superiority Ivonescimab’s novel MoA in PFS over pembrolizumab in a randomized Phase 3 raises the bar on efficacy and safety Ivonescimab P
Slide 8: CR-001: Cooperative, tetravalent PD-1 x VEGF bispecific antibody
CR-001 Cooperative, tetravalent PD-1 x VEGF bispecific antibody 8
Slide 9: Ivonescimab's novel, cooperative MoA hypothesized to drive enhanced anti-tumor activity
Ivonescimab’s novel, cooperative MoA hypothesized to drive enhanced anti-tumor activity while maintaining tolerability A VEGF drives tumor angiogenesis B Ivo’s cooperative binding blocks ✓Cooperativity: VEGF binding to and PD-L1 expression suppresses T cells PD-1 / PD-L1 interactions and inhibits VE
Slide 10: CR-001 is a highly potent PD-1 x VEGF bsAb designed to recapitulate ivonescimab
CR-001 is a highly potent PD-1 x VEGF bsAb designed to recapitulate ivonescimab’s cooperative pharmacology Same design as ivonescimab Potential for reduced AEs • Pairs anti-VEGF IgG & anti-PD-1 scFvs • Cooperative binding increases anti- • Avoids risk of alternative, clinically VEGF activity in TME,
Slide 11: CR-001 replicates ivonescimab's cooperative effect
CR-001 replicates ivonescimab’s cooperative effect, with greater binding to and inhibition of PD-1 signaling in presence of VEGF CR-001 lead, like ivonescimab, is more potent in … and also increases PD-1 binding on an NFAT reporter assay in the presence of VEGF… PD-1+ Jurkat cells in the presence of
Slide 12: Replicating ivonescimab's format requires complex protein engineering
Replicating ivonescimab’s tetravalent format and cooperativity, with stable scFvs, requires complex protein engineering Standard mAbs can be improved with established … but ensuring cooperative effect, stability, and developability protein engineering approaches… of tetravalent PD-(L)1 x VEGF bispec
Slide 13: CR-001 has potential to transform SoC across a multitude of oncology indications
CR-001 has potential to transform SoC across a multitude of oncology indications, with numerous first-in-class opportunities Anti-VEGF approvals Anti-PD-(L)1 approvals SOFT TISSUE BRAIN CHEST/THORACIC Alveolar soft part Glioblastoma Anti-VEGF and anti-PD(L)-1 Esophageal sarcoma approvals EGFRm non-s
Slide 14: Development programs across key late-stage competitors
Development programs across key late-stage competitors include numerous P3s with PFS & OS readouts, paving the way for CR-001 Timing Company Program Indication Population Combo Phase 2025 2026 2027 2028 1L PD-L1+ None 3 OS readout expected in 2025 mNSCLC Ivonescimab 1L squamous Chemo 3 OS readout ex
Slide 15: Parallel clinical development paths offer first-in-class and lower risk opportunities
Parallel clinical development paths offer potential for both first-in-class and lower risk opportunities for CR-001 1 Focus on potential first-in-class opportunities with rapid path to market (i.e., efficient development strategy, anticipated likelihood of PFS and OS success) • Numerous indications
Slide 16: CR-001 Phase 1 data offer potential for early de-risking
CR-001 Phase 1 data offer potential for early de-risking – a rarity for a solid tumor oncology program Phase 1 interim proof-of-concept data are a potentially significant value-generating event for CR-001. • Preliminary data from early Phase 1 cohorts provides substantial validation of program becau
Slide 17: Only four known constructs with potential for ivonescimab-like cooperative pharmacology
Only four known constructs with potential to exhibit ivonescimab-like cooperative pharmacology Anti-PD-1 scFv-based Anti-PD-1 VHH-based Anti-PD-L1 VHH-based Program CR-001 Ivonescimab LM-299 BNT327 / PM8002 Company Stage Preclinical Phase 3 (Global) Phase 1/2 initiation (China) Phase 2 (Global) / Ph
Slide 18: CR-001 preclinical data reproduces ivonescimab's breakthrough pharmacology
CR-001 preclinical data reproduces ivonescimab’s breakthrough pharmacology and is rapidly advancing to generate significant value Unprecedented third- CR-001’s proprietary party data validates Transformative MoA engineering is Built by the proven PD-1 x VEGF for $50B+ market designed to replicate Pa
Slide 19: CR-002 & CR-003: Topoisomerase inhibitor ADCs against validated targets
CR-002 & CR-003 Topoisomerase inhibitor ADCs against validated targets 19
Slide 20: CR-002 and CR-003 are potentially best-in-class topoisomerase inhibitor ADCs
CR-002 and CR-003 are potentially best-in-class topoisomerase inhibitor ADCs, with applicability across solid tumors Validated, undisclosed solid tumor Potential to synergize with CR-001 ADC targets and other immunotherapies • Each unique target has potential in • Each ADC can be leveraged in multip
Slide 21: ADCs with topoisomerase inhibitor payloads show best-in-modality efficacy and safety
ADCs with topoisomerase inhibitor payloads have demonstrated best-in-modality efficacy and safety CROSS-TRIAL COMPARISONS TopoI payload-based ADCs have demonstrated superior ORR vs. … and have shown much lower rates of peripheral neuropathy, a microtubule inhibitor-based ADCs in cross-trial comparis
Slide 22: Corporate
Corporate 22
Slide 23: Rapidly growing leadership team with deep biotech experience
Rapidly growing leadership team with deep experience building the next generation of biotechnology companies Jonathan Violin Chris Doughty Peter Harwin Alex Balcom Susan Moran Interim CEO Chief Business Officer Board of Directors Board of Directors Board of Directors Board of Directors 23
Slide 24: Financing expected to fund programs through key value-generating catalysts
Financing expected to fund Crescent programs through key anticipated value-generating catalysts 2025 2026 CR-001 (cooperative PD-1 x YE25 / 1Q26: IND 2H: Initial clinical data VEGF bsAb) CR-002 (undisclosed, ADC #1 with 2H: DC Mid-year: IND TopoI payload) CR-003 (undisclosed, ADC #2 with 1H: DC Topo
Slide 25: Estimated capitalization following close of transactions
Estimated capitalization following close of transactions Shares on an as- Expected ownership of converted basis the combined company GlycoMimetics • Shares of common stock outstanding 64,532,953 3.1% • Shares of common stock outstanding 105,137,814 Crescent Biopharma • Series A shares 298,298,000 96
Slide 26: Thank you
CRESCENT BIOPHARMA Thank you
Crescent Biopharma — Investor Presentation (November 2024) on 6ix